Prevenção das hepatites virais através de imunização

Abstract

Objective: To present an updated review and criticism of viral hepatitis A and B prevention by immunization. Summary of the findings: Viral hepatitis prevention is an enormous challenge to the public health systems of countries and the medical and scientific communities. Hepatitis viruses produce important morbimortality in the world, causing acute and chronic hepatic disease. There are highly efficient vaccines available on the market to prevent new infections by the A and B viruses. However, A and B viruses continue to be among the most commonly notified diseases preventable by vaccines. In this article, we discuss the vaccines used to prevent these infections, with the aim of expanding knowledge and the practice of prevention of these infectious diseases.Conclusions: Although the vaccines against A and B hepatitis are recommended for various risk groups, estimated vaccine coverage is still modest and many vaccination opportunities are lost. In order to reduce the incidence of A and B hepatitis, which are preventable by vaccines, it is necessary for physicians to encourage their patients to be vaccinated.

Prevalence and risk factors associated with HIV infection, hepatitis and syphilis in a state prison of São Paulo

“…Furthermore, this value could be underestimated since the post-vaccination seroconversion is not achieved in all vaccine recipients. 28 The prevalence of HBV infection in this study is considered high among incarcerated populations as compared to the general population, 13,29-31 as was also observed for the prevalence of HCV infection found in our study. 32 Risk factors for HBV infection observed resemble those found in other studies for incarcerated populations: parenteral and sexual components, jail time and age.…”

Age-Specific Seroprevalence of Anti-Hepatitis A Antibody Among 1-30 Years Old Population of Savadkuh, Mazandaran, Iran With Literature Review

“…Several HAV vaccines are available that are highly effective and provide long-lasting protection above 1-2 years of age, [1][2][4][7][8][10][11]. Cost and feasibility are two major barriers of public implementation of HAV vaccination [4][7][8][47] . Recommendation on usage of HAV vaccine varies considerably among countries.…”

“…Recommendation on usage of HAV vaccine varies considerably among countries. Guidelines from WHO [4], CDC [7], and experts [8][10][11] on HAV vaccine emphasize on cost-benefit [47] and sustainable preventative strategies in the context of other priorities such as other diseases, and their morbidity and mortality in any given countries. Consequently, large-scale and public vaccination programs applicable in hyperendemic developing countries are not recommended.…”

Epidemiological and serological aspects of hepatitis A among children and teenagers in the city of Santos: a cross-sectional study

“…Considering that young adults are more susceptible to the infection and that disease severity for this age range is high, healthcare professionals need to be aware of the prevalence of viral hepatitis A in order to identify, evaluate and control epidemics and calculate the impact of vaccination programs. [9][10][11][12] It is worth emphasizing that some studies have showed that vaccination against hepatitis A is capable of preventing disease dissemination during an outbreak, and also of protecting patients' household contacts. 13 In Brazil, there have been few prevalence studies on population samples representative of hepatitis A.…”